Lance Johnson, DPM
Foot & Ankle Surgery · Findlay, OHNPI 1174058630
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (49.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Arthrex at 31.7% of the total. Reporting peaked in 2021 at $5,192 and has fallen 92.1% since, to $410 in 2025.
Across 81 payments — averaging $119.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Rock Medical Orthopedics, Inc.$2K
- Stryker$1K
- Restor3d, Inc.$1K
- Integra Lifesciences Corporation$636
- DNE LLC$255
- plus $990 from 12 others
What the payments were for
- Travel & lodging$2,42525%
- Food & beverage$2,41825%
- Education$4,80050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 12 | $3,055 |
| Rock Medical Orthopedics, Inc. | 2 | $2,400 |
| Stryker(2 entities) | 26 | $1,198 |
| Restor3d, Inc. | 3 | $1,108 |
| Integra Lifesciences Corporation | 10 | $636 |
| DNE LLC | 1 | $255 |
| Access Pro Medical, LLC | 1 | $153 |
| Smith+Nephew | 6 | $152 |
| Bioventus LLC | 3 | $132 |
| Paragon 28, Inc. | 1 | $122 |
| Pacira Pharmaceuticals Incorporated | 1 | $120 |
| Kerecis Limited | 7 | $113 |
| Medshape, Inc. | 1 | $64 |
| Mimedx Group, Inc. | 2 | $51 |
| Organogenesis Inc. | 2 | $41 |
| Polynovo North America LLC | 1 | $19 |
| Acell, Inc. | 1 | $15 |
| Lifenet Health | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,643 in reported general payments places this provider in the 75th percentile of 429 foot & ankle surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 18 | $1,730 |
| Gabapentin | 34 | $790 |
| Meloxicam | 74 | $687 |
| Doxycycline Hyclate | 16 | $362 |
| Oxycodone Hcl | 49 | $282 |
| Ammonium Lactate | 26 | $255 |
| Ondansetron Hcl | 37 | $169 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $147 |
| Cephalexin | 11 | $146 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Findlay
- Emily MerrimanFindlay$17K
- Christopher HyerWorthington$4.7M
- Thomas LeePickerington$4M
- Jordan GrossmanAkron$2.5M
- Robert GorslineHilliard$1.4M
- Jonathan FeibelGahanna$1.4M
- Mark PrisselWorthington$1.2M
- Lee HladGahanna$440K
- Windy ColeKent$431K
- Elizabeth HewittGrove City$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.